Viatris Inc. (NASDAQ:VTRS) is one of the best low priced pharma stocks to buy now. On June 27, Viatris received approval from China’s National Medical Products Administration/NMPA for Yupelri (revefenacin) inhalation solution for the maintenance treatment of chronic obstructive pulmonary disease/COPD.
Yupelri is the first ever once-daily nebulized long-acting muscarinic antagonist/LAMA approved in China for COPD. Yupelri’s mechanism of action involves inhibiting M3 receptors in the smooth muscle, leading to bronchodilation.
A healthcare worker in a lab coat, holding a microscope and reflecting on the diagnosis of a patient.
This milestone triggers a one-time payment of $7.5 million from Viatris to Theravance Biopharma Inc. (NASDAQ:TBPH), which is expected in Q3 2025. Theravance Biopharma is also eligible to receive up to an additional $37.5 million in sales-related milestones and escalating royalties ranging from 14% to 20% on net sales of Yupelri in China.
Viatris Inc. is a healthcare company that operates in 4 segments: Developed Markets, Greater China, JANZ, and Emerging Markets.
Theravance Biopharma Inc. is a biopharmaceutical company that develops and commercializes medicines in the US.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
